BioNTech SE American Depositary Share - BNTX STOCK NEWS

BioNTech and Crescendo Biologics have announced a multi-target discovery collaboration to develop novel immunotherapies for cancer treatment. BioNTech will have exclusive worldwide development and commercialization rights to the therapies generated from this partnership. Crescendo will receive an upfront payment of $40 million, along with potential milestone payments exceeding $750 million, plus royalties on global net sales. The collaboration will leverage Crescendo's Humabody® VH platform, known for high-affinity binding and enhanced tissue penetration, over an initial term of three years.

BioNTech and Pfizer announced a collaboration to develop a potential mRNA-based vaccine for shingles, targeting the herpes zoster virus (HZV) that affects one in three individuals in the U.S. The partnership, their third in infectious diseases, aims to leverage BioNTech’s mRNA technology alongside Pfizer’s antigen technology. Under the agreement, BioNTech will receive $225 million upfront and can earn up to $200 million in future milestone payments. Clinical trials are expected to commence in the latter half of 2022, with Pfizer holding global commercialization rights.

Pfizer and BioNTech have announced a collaboration to develop an mRNA-based vaccine for shingles, targeting the herpes zoster virus. This partnership marks their third collaboration in infectious diseases, building on their previous successes with COVID-19 and influenza vaccines. Under the agreement, BioNTech will receive $225 million upfront, while Pfizer will secure $25 million for its proprietary antigen sequences. Clinical trials are set to begin in the second half of 2022, with cost-sharing and profit-sharing on potential vaccine sales.

The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include booster doses for individuals aged 12 and older. The booster maintains the same 30-µg dosage as the primary series, addressing rising COVID-19 cases. Additionally, the waiting time for the booster after primary series completion has been reduced from six to five months. A third primary series dose is also authorized for immunocompromised children aged 5-11. Pfizer and BioNTech have delivered 1 billion doses to low- and middle-income countries, with an additional billion expected in 2022.

BioNTech SE (Nasdaq: BNTX) announced that CEO and Co-founder Ugur Sahin will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 am ET. A live webcast of the presentation will be accessible on the Company’s website, with a replay available for 30 days post-conference.

BioNTech is a leading biopharmaceutical company specializing in innovative immunotherapies for cancer and other serious diseases. It develops mRNA vaccines and collaborates with major pharmaceutical partners, advancing its oncology pipeline and infectious disease therapies.

Pfizer and BioNTech announced an agreement with the European Commission to deliver over 200 million additional doses of their COVID-19 vaccine, COMIRNATY, in 2022. This brings the total planned doses for the year to more than 650 million. The contract will include potential vaccines adapted for the Omicron variant at no additional cost. Pfizer and BioNTech had previously agreed to supply 900 million doses to the EC for 2022 and 2023, with an option for up to an additional 900 million doses.

On December 9, 2021, Pfizer and BioNTech announced the FDA's Emergency Use Authorization (EUA) expansion for a COVID-19 vaccine booster for individuals aged 16 and older. The booster, administered at least six months after the primary series, boasts the same formulation and dosage strength as the initial doses. Phase 3 trial data showed a 95% relative vaccine efficacy after the booster. This authorization, significant amid the emergence of variants like Omicron, reinforces the companies' commitment to global vaccination efforts as they prepare a supplemental Biologics License Application.

The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine booster, now available for individuals aged 16 and older. Administered at least six months post-primary series, the booster has shown a 95% efficacy in combating symptomatic COVID-19 compared to non-booster recipients. Pfizer and BioNTech plan to submit a supplemental Biologics License Application to formalize this authorization. The companies will continue supplying vaccines under existing agreements with the U.S. government through April 2022.

BioNTech SE (Nasdaq: BNTX) has scheduled a digital press conference for December 8, 2021, at 3:00 PM CET to discuss initial laboratory study results regarding the impact of the Omicron variant on COVID-19 vaccine-induced immune responses. The conference will be conducted in English and streamed online, with no on-site attendance for journalists. Recordings and presentations will be available later on their website.

BioNTech is known for its development of mRNA-based therapies for cancer and infectious diseases, collaborating with various global pharmaceutical partners.